The new ministry could be named Ministry of Pharmaceuticals and Medical Devices, Minister of State for Chemicals and Fertilisers Mansukh L Mandaviya said in a written reply in the Lok Sabha.
Another tough past week for pharmaceutical stocks, many have sunk on weak Q1 results due to destocking of channel on account of GST rollout and US pricing pressures
While such rules are common elsewhere in the world and adhered to by large pharmaceutical companies, they are not set in stone in India, where campaigners have long demanded a crackdown on unethical selling practices. These have included gifts ranging from electrical appliances to foreign junkets to encourage doctors and pharmacists to prescribe and stock certain medications.
"The company has received approval from the United States Food and Drug Administration (USFDA) for its ANDA for Doxycycline capsules USP 75 mg and 100 mg," Alembic Pharmaceuticals said in a BSE filing today.
Natco Pharma announces successful EIR from the US Food and Drug Administration (USFDA) for the inspection conducted at its drug manufacturing facility in Kothur village in Mahabubnagar district during January 16–24, 2017, the company said in a BSE filing today.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg," Aurobindo Pharma said in a BSE filing today.
Vozet is indicated for the treatment of allergic Rhinitis and chronic Urticaria.
Government is looking at introducing a new National Pharmaceuticals Policy and is already in the process of working out details.
Drug firm Zydus Cadila today said it has received tentative nod from the US health regulator to market Fingolimod capsules used for treatment of multiple sclerosis
Drug firm Ajanta Pharma today said its promoters have sold 27 lakh shares in the company representing about 3.07 percent of its paid-up capital
Along with establishing a new plant, the company is assessing new products from its global respiratory and vaccines pipeline and reviewing these for a possible launch in India.
In case you missed it, here's a recap of all that happened in the pharma sector this week.
In an interview to CNBC-TV18, Habil F Khorakiwala, Founder, Chairman & Group CEO of Wockhardt spoke about the latest happenings in his company and sector.
The company grew from being a domestic Indian pharmaceutical firm to a global pharmaceutical major. It is now the 4th largest generics pharmaceutical player by market capitalisation in the world.
The Indian pharmaceutical market size is expected to grow to USD 100 billion by 2025. By 2020, India is likely to be among the top-3 pharmaceutical markets by incremental growth and the sixth largest market globally in absolute size. The Indian packaging industry constitutes about 4 percent of the global packaging industry making it a crucial factor in India's pharma growth story.
Everything you need to know to get up to speed with the world of pharma.
Indian drug cos are falling woefully short of their global peers in arming medical representatives with desired digital tools, according to a new survey of field representatives by Indegene,
The USFDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market. Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda (mesalamine), the company said in a BSE filing.
IDA (Industrial Development Agency) Ireland CEO Martin D Shanahan said that Indian companies based in the UK are welcome to shift operations in Ireland as it will continue to remain part of the European Union even after Brexit.
In an interview to CNBC-TV18, Jaspal Bindra, Executive Chairman of Centrum Group spoke about the theme of the conference and what the underlying conversations are considering the record highs that the market is sitting at.
The pharmaceutical sector has been missing for the recent rally on Dalal Street and the Nifty Pharma Index is down 10 percent in May while the Nifty gained over 3 percent.
The one-day strike is likely to reduce the supply of drugs to the market, thereby affecting patients. However, medicine shops inside hospitals and day-and-night outlets will remain open.
"There are major structural changes taking place in the pharma business across the globe whether it is US or India or Japan and that will put pressure," said Kamal K. Sharma, vice chairman of Lupin in an exclusive interview to Moneycontrol.
The S&P BSE Sensex pared gains in the last two trading sessions and eventually closed in the green largely led by weak global cues.
The pharma major reported 49.2 percent YoY decline in the net profit to Rs 380.2 crore in the fourth quarter ended March on account of drop in US sales and a one-time provisioning